All In Biotech

Drug Trial Radar · NCT00002548

SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma

Standard Dose Versus Myeloablative Therapy for Previously Untreated Symptomatic Multiple Myeloma, A Phase III Intergroup Study

Last checked: Nov 20, 2026Latest source record: Mar 6, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 899 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

899

Actual

Start

Jan 1994

Primary completion

Oct 2003

Study completion Nov 2006

Sponsor

Lead sponsor
SWOG Cancer Research NetworkResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI); Cancer and Leukemia Group B; Eastern Cooperative Oncology Group
First posted
Aug 11, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy and radiation therapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy and radiation therapy and kill more cancer cells. It is not yet known which treatment regimen is more effective for multiple myeloma. PURPOSE: Randomized phase III trial to compare the effectiveness of melphalan, total-body irradiation, and peripheral stem cell transplantation with that of combination chemotherapy in treating patients who have previously untreated multiple myeloma.

Conditions

  • Multiple Myeloma

Interventions

  • recombinant interferon alfaBiological

    3 million units/m2 SQ Monday-Wednesday -Friday (3 times a week)

  • carmustineDrug

    20 mg/m2 I.V. day 1 q 35 days

  • cyclophosphamideDrug

    1.5 g/m2 in 100 ml of D5W, IV intravenously over 1 hour every 3 hour x 3 (total dose 4.5 g/m2)

  • dexamethasoneDrug

    40 mg/day PO or IVPB days 1-4, 9-12, 17-20 q 5 weeks

  • doxorubicin hydrochlorideDrug

    10 mg/m2/day continuous 1 - 4 q 5 weeks

  • melphalanDrug

    140 mg/m2 is given IV within 30 minutes of constitution on Day -5

  • prednisoneDrug

    40 mg/m2 PO days 1-7 q 35 days

  • vincristine sulfateDrug

    0.5 mg/day continuous 1 - 4 q 5 weeks

  • allogeneic bone marrow transplantationProcedure

    day 0

  • autologous bone marrow transplantationProcedure

    day 0

  • peripheral blood stem cell transplantationProcedure

    day 0

  • radiation therapyRadiation

    administered in fractionated doses of 150 cGy, 6 - 10 hours apart bid, on Days -4, -3, -2, and -1 (Total 1,200 cGy)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. survivalTime frame: 3 years from randomization

Locations

34 sites in 1 country. Site status is shown where the registry gives one.

  • CCOP - Scottsdale Oncology Program

    Scottsdale, Arizona

  • CCOP - Colorado Cancer Research Program, Inc.

    Denver, Colorado

  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida

  • Robert H. Lurie Comprehensive Cancer Center, Northwestern University

    Chicago, Illinois

  • Veterans Affairs Medical Center - Lakeside Chicago

    Chicago, Illinois

  • CCOP - Evanston

    Evanston, Illinois

  • CCOP - Illinois Oncology Research Association

    Peoria, Illinois

  • CCOP - Carle Cancer Center

    Urbana, Illinois

  • Indiana University Cancer Center

    Indianapolis, Indiana

  • Veterans Affairs Medical Center - Indianapolis (Roudebush)

    Indianapolis, Indiana

  • CCOP - Iowa Oncology Research Association

    Des Moines, Iowa

  • CCOP - Ochsner

    New Orleans, Louisiana

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland

  • New England Medical Center Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • CCOP - Ann Arbor Regional

    Ann Arbor, Michigan

  • CCOP - Kalamazoo

    Kalamazoo, Michigan

  • CCOP - Duluth

    Duluth, Minnesota

  • University of Minnesota Cancer Center

    Minneapolis, Minnesota

  • Mayo Clinic Cancer Center

    Rochester, Minnesota

  • CCOP - Metro-Minnesota

    Saint Louis Park, Minnesota

  • Veterans Affairs Medical Center - New York

    New York, New York

  • NYU School of Medicine's Kaplan Comprehensive Cancer Center

    New York, New York

  • University of Rochester Cancer Center

    Rochester, New York

  • Albert Einstein Comprehensive Cancer Center

    The Bronx, New York

  • Ireland Cancer Center

    Cleveland, Ohio

  • CCOP - Toledo Community Hospital Oncology Program

    Toledo, Ohio

  • CCOP - Geisinger Clinic and Medical Center

    Danville, Pennsylvania

  • Hahnemann University Hospital

    Philadelphia, Pennsylvania

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • University of Pittsburgh Cancer Institute

    Pittsburgh, Pennsylvania

  • CCOP - Marshfield Medical Research and Education Foundation

    Marshfield, Wisconsin

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Veterans Affairs Medical Center - Milwaukee (Zablocki)

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.